We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for United Therapeutics (UTHR - Free Report) . Shares have added about 1.1% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is United Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Q3 Earnings & Sales Beat Estimates
United Therapeutics’ third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings rose 19% year over year on the back of higher product sales.
Revenues were $748.9 million, beating the Zacks Consensus Estimate of $717.5 million. Revenues rose 23% year over year, driven by meaningful growth of key products — Tyvaso, Orenitram and Unituxin.
Quarter in Detail
Tyvaso DPI recorded sales of $274.6 million, up 34% year over year, while sales from nebulized Tyvaso were $159.2 million, up 32%.
Overall, Tyvaso sales were $433.8 million, up 33% year over year, driven by higher volumes and continued growth in commercialization utilization by PH-ILD patients. This reported figure beat the Zacks Consensus Estimate of $410 million and our model estimate of $375 million.
Remodulin (including Remunity Pump) sales fell 2% year over year to $128.3 million due to a decline in the drug’s ex-U.S. sales.
Sales of Orenitram rose 23% year over year to $113.2 million, driven by increased demand for the drug.
Unituxin sales rose 19% year over year to $61.1 million. Adcirca sales were $7.0 million, down 4%.
Research and development expenses were $103.5 million in the quarter, up 22% year over year, driven by increased expenditures related to manufactured organ and organ alternative projects.
Selling, general and administrative expenses surged 72% to $219.2 million in the quarter. This uptick was due to an increase in personnel expenses.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates.
VGM Scores
Currently, United Therapeutics has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. Following the exact same course, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, United Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?
A month has gone by since the last earnings report for United Therapeutics (UTHR - Free Report) . Shares have added about 1.1% in that time frame, underperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is United Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Q3 Earnings & Sales Beat Estimates
United Therapeutics’ third-quarter 2024 earnings of $6.39 per share beat the Zacks Consensus Estimate of $6.18. Earnings rose 19% year over year on the back of higher product sales.
Revenues were $748.9 million, beating the Zacks Consensus Estimate of $717.5 million. Revenues rose 23% year over year, driven by meaningful growth of key products — Tyvaso, Orenitram and Unituxin.
Quarter in Detail
Tyvaso DPI recorded sales of $274.6 million, up 34% year over year, while sales from nebulized Tyvaso were $159.2 million, up 32%.
Overall, Tyvaso sales were $433.8 million, up 33% year over year, driven by higher volumes and continued growth in commercialization utilization by PH-ILD patients. This reported figure beat the Zacks Consensus Estimate of $410 million and our model estimate of $375 million.
Remodulin (including Remunity Pump) sales fell 2% year over year to $128.3 million due to a decline in the drug’s ex-U.S. sales.
Sales of Orenitram rose 23% year over year to $113.2 million, driven by increased demand for the drug.
Unituxin sales rose 19% year over year to $61.1 million. Adcirca sales were $7.0 million, down 4%.
Research and development expenses were $103.5 million in the quarter, up 22% year over year, driven by increased expenditures related to manufactured organ and organ alternative projects.
Selling, general and administrative expenses surged 72% to $219.2 million in the quarter. This uptick was due to an increase in personnel expenses.
How Have Estimates Been Moving Since Then?
In the past month, investors have witnessed an upward trend in fresh estimates.
VGM Scores
Currently, United Therapeutics has a nice Growth Score of B, however its Momentum Score is doing a bit better with an A. Following the exact same course, the stock was allocated a grade of A on the value side, putting it in the top quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, United Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.